Antibody responses to yellow fever vaccine in 9 to 11-month-old Malian and Ghanaian children

References

• SAGE Working Group. Background paper on yellow fever vaccine. 2013. Available from: www.who.int/immunization/sage/meetings/2013/
   Google Scholar
• Kollmann TR, Marchant A. Towards predicting protective vaccine responses in the very young. Trends Immunol. 2016;37(8):523–534.
   PubMed Web of Science ®Google Scholar
• Collaborative Group for Studies of Yellow Fever, V. A randomised double-blind clinical trial of two yellow fever vaccines prepared with substrains 17DD and 17D-213/77 in children nine-23 months old. Mem Inst Oswaldo Cruz. 2015;110(6):771–780.
   PubMed Web of Science ®Google Scholar
• Roy Chowdhury P, Meier C, Laraway H, et al. Immunogenicity of yellow fever vaccine coadministered with MenAfriVac in healthy infants in Ghana and Mali. Clin Infect Dis. 2015;61(Suppl 5):S586–93.
   PubMedGoogle Scholar
• Collaborative group for studies on yellow fever, v. Duration of post-vaccination immunity against yellow fever in adults. Vaccine. 2014;32(39):4977–4984.
   PubMed Web of Science ®Google Scholar
• Nascimento Silva JR, Camacho LAB, Siqueira MM, et al. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella. Vaccine. 2011;29(37):6327–6334.
   PubMed Web of Science ®Google Scholar
• Clarke E, Saidu Y, Adetifa JU, et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles-rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia. Lancet Glob Health. 2016;4(8):e534–47.
   PubMed Web of Science ®Google Scholar
• de Melo AB, Da Silva MDPC, Magalhães MCF, et al. Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil. Am J Trop Med Hyg. 2011;85(4):739–747.
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Ten yearly yellow fever booster vaccinations may still be justified. J Travel Med. 2018;25(1).
   PubMedGoogle Scholar
• Roukens AHE, van Halem K, de Visser AW, et al. Long-term protection after fractional-dose yellow fever vaccination: follow-up study of a randomized, controlled, noninferiority trial. Ann Intern Med. 2018;169(11):761–765.
   PubMed Web of Science ®Google Scholar
• Lindsey NP, Horiuchi KA, Fulton C, et al. Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers. J Travel Med. 2018;25(1).
   PubMedGoogle Scholar
• Vaccines and vaccination against yellow fever. WHO position paper – june 2013. Wkly Epidemiol Rec. 2013;88(27):269–283.
   PubMedGoogle Scholar
• World Health Organization. Vaccines and vaccination against yellow fever: WHO position paper, june 2013–recommendations. Vaccine. 2015;33(1):76–77.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO position on the use of fractional doses - june 2017, addendum to vaccines and vaccination against yellow fever WHO: position paper - june 2013. Vaccine. 2017;35(43):5751–5752.
   PubMed Web of Science ®Google Scholar
• World Health, Organization. Yellow fever vaccine. WHO position paper. Wkly Epidemiol Rec. 2003;78(40):349–359.
   PubMedGoogle Scholar
• World Health Organization. Yellow fever vaccine: WHO position on the use of fractional doses - June 2017. Wkly Epidemiol Rec. 2017;92(25):345–350.
   PubMedGoogle Scholar
• Vannice K, Wilder-Smith A, Hombach J. Fractional-dose yellow fever vaccination - advancing the evidence base. N Engl J Med. 2018;379(7): 603–605.
   PubMed Web of Science ®Google Scholar
• Jones KD, Berkley JA. Severe acute malnutrition and infection. Paediatr Int Child Health. 2014;34(Suppl 1):S1–S29.
   PubMedGoogle Scholar
• Unicef, World Bank. Joint child malnutrition estimates. 2017. www.who.int/nutgrowthdb/estimates2016/en
   Google Scholar
• Savy M, Edmond K, Fine PEM, et al. Landscape analysis of interactions between nutrition and vaccine responses in children. J Nutr. 2009;139(11):2154S–218S.
   PubMed Web of Science ®Google Scholar
• UN Inter-agency Group for Estimation of Child mortality. Levels and trends in child mortality. 2017. www.un.org/ … /mortality/child-mortality-report-2017.shtml
   Google Scholar
• Blake LE, Garcia-Blanco MA. Human genetic variation and yellow fever mortality during 19th century U.S. epidemics. MBio. 2014;5(3):e01253–14.
   PubMed Web of Science ®Google Scholar
• Meningitis Vaccine’ Project. Research and development. Available from: http://www.meningvax.org/researchdevelopment.html
   Google Scholar
• World Health Organization. Results from MenA vaccine randomized controlled trials in infants and young children – Executive summary for SAGE. 2014.
   Google Scholar
• World Health Organization: Regional Office for Africa. Yellow fever. Available from: afro.who.int/health-topics/yellow-fever
   Google Scholar
• Singh J. International conference on harmonization of technical requirements for registration of pharmaceuticals for human use. J Pharmacol Pharmacother. 2015;6(3):185–187.
   PubMed Web of Science ®Google Scholar
• Dixon JR Jr. The international conference on harmonization good clinical practice guideline.Qual Assur. 1998;6(2):65–74.
   PubMedGoogle Scholar
• Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17(7):1055–1065.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Child growth standards. 2007. Available from: http://www.who.int/childgrowth/standards/weight_for_age/en/
   Google Scholar
• StataCorp. Stata statistical software: release 14. College Station, TX:: StataCorp LP; 2015.
   Google Scholar
• Jabara HH, Boyden SE, Chou J, et al. A missense mutation in TFRC, encoding transferrin receptor 1, causes combined immunodeficiency. Nat Genet. 2016;48(1):74–78.
   PubMed Web of Science ®Google Scholar
• Dos Santos CN, Post PR, Carvalho R, et al. Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213. Virus Res. 1995;35(1):35–41.
   PubMed Web of Science ®Google Scholar
• Martins RM, Maia MDLS, Farias RHG, et al. 17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study. Hum Vaccin Immunother. 2013;9(4):879–888.
   PubMed Web of Science ®Google Scholar
• Pfister M, Kürsteiner O, Hilfiker H, et al. Immunogenicity and safety of BERNA-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial. Am J Trop Med Hyg. 2005;72(3):339–346.
   PubMed Web of Science ®Google Scholar
• Izurieta RO, Macaluso M, Watts DM, et al. Anamnestic immune response to dengue and decreased severity of yellow fever. J Glob Infect Dis. 2009;1(2):111–116.
   PubMedGoogle Scholar
• Moore SE, Collinson AC, Fulford AJC, et al. Effect of month of vaccine administration on antibody responses in The Gambia and Pakistan. Trop Med Int Health. 2006;11(10):1529–1541.
   PubMed Web of Science ®Google Scholar
• Klein SL, Marriott I, Fish EN. Sex-based differences in immune function and responses to vaccination. Trans R Soc Trop Med Hyg. 2015;109(1):9–15.
   PubMed Web of Science ®Google Scholar
• Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626–638.
   PubMed Web of Science ®Google Scholar
• Idoko OT, Okolo SN, Plikaytis B, et al. The impact of pre-existing antibody on subsequent immune responses to meningococcal A-containing vaccines. Vaccine. 2014;32(33):4220–4227.
   PubMed Web of Science ®Google Scholar